{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:55:11Z","timestamp":1788508511340,"version":"build-2803163510"},"reference-count":38,"publisher":"BMJ","issue":"11","funder":[{"name":"Naestved-Slagelse-Ringsted Hospitals"},{"DOI":"10.13039\/501100000724","name":"Health Foundation","doi-asserted-by":"publisher","award":["#15-B-0234"],"award-info":[{"award-number":["#15-B-0234"]}],"id":[{"id":"10.13039\/501100000724","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006356","name":"University of Southern Denmark","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006356","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Patients with chronic obstructive pulmonary disease (COPD) are undertreated with beta-blockers following myocardial infarction (MI), possibly due to fear for acute exacerbations of COPD (AECOPD). Is beta-blocker use associated with increased risk of AECOPD in patients following first-time MI?<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Danish nationwide study of patients with COPD following hospitalisation for MI from 2003 to 2015. Multivariable, time-dependent Cox regression accounting for varying beta-blocker use based on claimed prescriptions during up to 13 years of follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 10\u2009884 patients with COPD were discharged after first-time MI. The 1-year rate of AECOPD was 35%, and 65% used beta-blockers at 1\u2009year. Beta-blocker use was associated with a lower risk of AECOPD (multivariable-adjusted HR 0.78, 95% CI 0.74\u20130.83). This association was independent of the type of MI (HR 0.70, 95%\u2009CI 0.59\u20130.83 in ST-elevation MI (STEMI) and HR 0.80, 95%\u2009CI 0.75\u20130.84 in non-STEMI), presence or absence of heart failure (HR 0.82, 95%\u2009CI 0.74\u20130.90 and HR 0.77, 95%\u2009CI 0.72\u20130.82, respectively), beta-blocker dosage and type, as well as exacerbation severity. Results were similar in 1118 patients with full data on COPD severity and symptom burden (median forced expiratory volume in 1\u2009s as percentage of predicted was 46 and majority had moderate dyspnoea), and in 1358 patients with severe COPD and frequent AECOPD with a high 1-year rate of AECOPD of 70%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Beta-blocker use was not associated with increased risk of AECOPD following MI. This finding was independent of COPD severity, symptom burden and exacerbation history, and supports the safety of beta-blockers in patients with COPD, including high-risk patients with severe disease.<\/jats:p><\/jats:sec>","DOI":"10.1136\/thoraxjnl-2019-214206","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T21:21:56Z","timestamp":1597958516000},"page":"928-933","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Beta-blocker use and acute exacerbations of COPD following myocardial infarction: a Danish nationwide cohort study"],"prefix":"10.1136","volume":"75","author":[{"given":"Daniel B","family":"Rasmussen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uffe","family":"Bodtger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Lamberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Torp-Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Gislason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus T","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"key":"2020101607253560000_75.11.928.1","first-page":"267","article-title":"ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"2016","author":"Roffi","year":"2015","journal-title":"European Heart Journal"},{"key":"2020101607253560000_75.11.928.2","first-page":"1","article-title":"ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"2017","author":"Ibanez","year":"2017","journal-title":"European Heart Journal"},{"key":"2020101607253560000_75.11.928.3","doi-asserted-by":"crossref","unstructured":"Rasmussen DB , Bodtger U , Lamberts M , et al . Beta-blocker, aspirin, and statin usage after first-time myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark. European Heart Journal - Quality of Care and Clinical Outcomes;9.doi:10.1093\/ehjqcco\/qcy063","DOI":"10.1093\/ehjqcco\/qcy063"},{"key":"2020101607253560000_75.11.928.4","doi-asserted-by":"publisher","DOI":"10.1378\/chest.127.3.818"},{"key":"2020101607253560000_75.11.928.5","first-page":"CD003566","article-title":"Cardioselective beta-blockers for chronic obstructive pulmonary disease","volume":"4","author":"Salpeter","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"2020101607253560000_75.11.928.6","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1513\/AnnalsATS.201708-626OC","article-title":"\u03b2-blocker therapy and clinical outcomes in patients with moderate chronic obstructive pulmonary disease and heightened cardiovascular risk. an observational substudy of SUMMIT","volume":"15","author":"Dransfield","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"2020101607253560000_75.11.928.7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12931-017-0609-7","article-title":"Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD)","volume":"18","author":"Duffy","year":"2017","journal-title":"Respir Res"},{"key":"2020101607253560000_75.11.928.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2012.07.080"},{"key":"2020101607253560000_75.11.928.9","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-201945"},{"key":"2020101607253560000_75.11.928.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.07.043"},{"key":"2020101607253560000_75.11.928.11","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.2147\/COPD.S145913","article-title":"Impact of selective and nonselective beta-blockers on the risk of severe exacerbations in patients with COPD","volume":"12","author":"Huang","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2020101607253560000_75.11.928.12","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207251"},{"key":"2020101607253560000_75.11.928.13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d2549"},{"key":"2020101607253560000_75.11.928.14","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.112"},{"key":"2020101607253560000_75.11.928.15","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2016-208412"},{"key":"2020101607253560000_75.11.928.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909883"},{"key":"2020101607253560000_75.11.928.17","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1056\/NEJMoa1908142","article-title":"Metoprolol for the prevention of acute exacerbations of COPD","volume":"381","author":"Dransfield","year":"2019","journal-title":"N Engl J Med"},{"key":"2020101607253560000_75.11.928.18","doi-asserted-by":"crossref","unstructured":"M\u00fcllerov\u00e1 H , Shukla A , Hawkins A , et al . Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study. BMJ Open 2014;4:e006171. doi:10.1136\/bmjopen-2014-006171","DOI":"10.1136\/bmjopen-2014-006171"},{"key":"2020101607253560000_75.11.928.19","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/pds.4372","article-title":"Methods for time-varying exposure related problems in pharmacoepidemiology: an overview","volume":"27","author":"Pazzagli","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2020101607253560000_75.11.928.20","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S91125"},{"key":"2020101607253560000_75.11.928.21","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-014-9930-3"},{"key":"2020101607253560000_75.11.928.22","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2147\/CLEP.S99489","article-title":"Danish register of chronic obstructive pulmonary disease","volume":"8","author":"Lange","year":"2016","journal-title":"Clin Epidemiol"},{"key":"2020101607253560000_75.11.928.23","doi-asserted-by":"crossref","unstructured":"Sundb\u00f8ll J , Adelborg K , Munch T , et al . Positive predictive value of cardiovascular diagnoses in the Danish national patient registry: a validation study. BMJ Open 2016;6:e012832. doi:10.1136\/bmjopen-2016-012832","DOI":"10.1136\/bmjopen-2016-012832"},{"key":"2020101607253560000_75.11.928.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.01.012"},{"key":"2020101607253560000_75.11.928.25","doi-asserted-by":"publisher","DOI":"10.7326\/M13-1581"},{"key":"2020101607253560000_75.11.928.26","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi705"},{"key":"2020101607253560000_75.11.928.27","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.rmed.2015.10.015","article-title":"Medically treated exacerbations in COPD by gold 1-4: a valid, robust, and seemingly low-biased definition","volume":"109","author":"Ingebrigtsen","year":"2015","journal-title":"Respir Med"},{"key":"2020101607253560000_75.11.928.28","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2011-201518"},{"key":"2020101607253560000_75.11.928.29","unstructured":"GOLD . Global initiative for chronic obstructive lung disease (gold), 2019. Available: http:\/\/goldcopd.org\/ [Accessed 23 Jan 2019]."},{"key":"2020101607253560000_75.11.928.30","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm031"},{"key":"2020101607253560000_75.11.928.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.06.003"},{"key":"2020101607253560000_75.11.928.32","first-page":"1887","article-title":"Robust causal inference using directed acyclic graphs: the R package 'dagitty'","volume":"45","author":"Textor","year":"2016","journal-title":"Int J Epidemiol"},{"key":"2020101607253560000_75.11.928.33","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2147\/CLEP.S147175","article-title":"Conditioning on future exposure to define study cohorts can induce bias: the case of low-dose acetylsalicylic acid and risk of major bleeding","volume":"9","author":"Lund","year":"2017","journal-title":"Clin Epidemiol"},{"key":"2020101607253560000_75.11.928.34","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00222511"},{"key":"2020101607253560000_75.11.928.35","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-018-0535-5","article-title":"Simulation shows undesirable results for competing risks analysis with time-dependent covariates for clinical outcomes","volume":"18","author":"Poguntke","year":"2018","journal-title":"BMC Med Res Methodol"},{"key":"2020101607253560000_75.11.928.36","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.001888"},{"key":"2020101607253560000_75.11.928.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2007.06.003"},{"key":"2020101607253560000_75.11.928.38","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-010-1609-1"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thoraxjnl-2019-214206","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T14:27:27Z","timestamp":1602858447000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thoraxjnl-2019-214206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,10,16]]},"published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1136\/thoraxjnl-2019-214206"],"URL":"https:\/\/doi.org\/10.1136\/thoraxjnl-2019-214206","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]}}}